BioPharma Resources

Drug Trial Radar · NCT07560033

A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects

A Randomized, Open-Label, Parallel-Controlled Phase I Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of a Single Subcutaneous Injection of CM326 Via Different Delivery Devices in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Oct 1, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

  • CM326(formulation 1)Drug

    subcutaneous injection

  • CM326(formulation 2)Drug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration (Cmax)Time frame: Pre-dose at day 1 to Day 113
  2. Area under the concentration-time curve from zero to infinity (AUCinf)Time frame: Pre-dose at day 1 to Day 113

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.